<SEC-DOCUMENT>0001615219-23-000055.txt : 20230615
<SEC-HEADER>0001615219-23-000055.hdr.sgml : 20230615
<ACCEPTANCE-DATETIME>20230614184712
ACCESSION NUMBER:		0001615219-23-000055
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230614
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230615
DATE AS OF CHANGE:		20230614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Salarius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001615219
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465087339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36812
		FILM NUMBER:		231015532

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		346-772-0346

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Flex Pharma, Inc.
		DATE OF NAME CHANGE:	20140730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>flks-20230614.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:e6b66bbe-b480-4cda-9fdf-3b125d93c7f5,g:fb5a7ef5-6d67-46bd-a018-440b61aed82e,d:90c16221fc3f46c4824f5bb179bd1873--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>flks-20230614</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M180L2ZyYWc6OWJmMTk2ZTAwMzkyNDFiNzkwODFhODM0ZGIxOTU3MGIvdGFibGU6N2I5ZDg1YjFiYzY2NDFmMmE1ZGI5OWEwZWFiNjRkMDcvdGFibGVyYW5nZTo3YjlkODViMWJjNjY0MWYyYTVkYjk5YTBlYWI2NGQwN18xLTEtMS0xLTQwNzE3_a49d8f98-0ded-4b41-a67a-87cd25129be8">0001615219</ix:nonNumeric><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M180L2ZyYWc6OWJmMTk2ZTAwMzkyNDFiNzkwODFhODM0ZGIxOTU3MGIvdGFibGU6N2I5ZDg1YjFiYzY2NDFmMmE1ZGI5OWEwZWFiNjRkMDcvdGFibGVyYW5nZTo3YjlkODViMWJjNjY0MWYyYTVkYjk5YTBlYWI2NGQwN18yLTEtMS0xLTQwNzE3_333b8a7c-f1d6-48c2-9760-5965a15453fe">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="flks-20230614.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i90c16221fc3f46c4824f5bb179bd1873_1"></div><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.527%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C.&#160; 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE2_e36fc5b0-a971-4347-8255-36e13a591f0b">8-K</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT<br/>Pursuant to Section 13 or 15(d) of the<br/>Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N18yMjM_a7615e28-8339-462a-b722-d9bd8450dc92">June 14, 2023</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE3_5231f271-1b89-4114-9d21-9e82ec1839ed">SALARIUS PHARMACEUTICALS, INC.</ix:nonNumeric> <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8wLTAtMS0xLTQwNzE3_9598cced-1830-43ed-aa07-d10c3de9dc81">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8wLTItMS0xLTQwNzE3_70b093df-788f-49a9-931f-df41d17edd33">001-36812</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8wLTYtMS0xLTQwNzE3_0e58ea57-97e9-49a5-82ae-9951a196453b">46-5087339</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(IRS Employer Identification Number)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTAtMS0xLTQwNzE3L3RleHRyZWdpb246MjZhOGVjMWVlZTExNDg3NThkNzRiZDgxMGM5ZDEyMWRfNQ_657e2a29-2500-431b-ad0c-5ea113235e99">2450 Holcombe Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTAtMS0xLTQwNzE3L3RleHRyZWdpb246MjZhOGVjMWVlZTExNDg3NThkNzRiZDgxMGM5ZDEyMWRfOA_7f3b07b5-aa32-4fda-91d0-d12acee01cc8">Suite X</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTAtMS0xLTQwNzE3L3RleHRyZWdpb246MjZhOGVjMWVlZTExNDg3NThkNzRiZDgxMGM5ZDEyMWRfMTE_0ffd9cc1-7208-4acb-9be0-763d0f2593a8">Houston</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTAtMS0xLTQwNzE3L3RleHRyZWdpb246MjZhOGVjMWVlZTExNDg3NThkNzRiZDgxMGM5ZDEyMWRfMTU_622cf71b-e3b7-430a-ba60-d8feb81abc3a">TX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTQtMS0xLTQwNzE3_95310ab2-b16a-4a5e-9bdb-1f886f02e1aa">77021</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE4_1f791fda-b0ef-4e42-9499-319a93d2b251">832</ix:nonNumeric>) <ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE5_f21b001c-7a6c-443b-ba96-26019f9b6411">834-9144</ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6YmUyYzVmOGIwMDVkNDZiZDgyZGRiMDQyN2IyZGFiMzMvdGFibGVyYW5nZTpiZTJjNWY4YjAwNWQ0NmJkODJkZGIwNDI3YjJkYWIzM18wLTAtMS0xLTQwNzE3_2f967157-e4bc-4d9f-9566-973a1ae271d0">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6YmUyYzVmOGIwMDVkNDZiZDgyZGRiMDQyN2IyZGFiMzMvdGFibGVyYW5nZTpiZTJjNWY4YjAwNWQ0NmJkODJkZGIwNDI3YjJkYWIzM18xLTAtMS0xLTQwNzE3_7c78a720-422b-4943-83ea-cbad5fc9b831">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6YmUyYzVmOGIwMDVkNDZiZDgyZGRiMDQyN2IyZGFiMzMvdGFibGVyYW5nZTpiZTJjNWY4YjAwNWQ0NmJkODJkZGIwNDI3YjJkYWIzM18yLTAtMS0xLTQwNzE3_5776e6a5-3ca2-4278-98b9-87b06bb22fa6">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6YmUyYzVmOGIwMDVkNDZiZDgyZGRiMDQyN2IyZGFiMzMvdGFibGVyYW5nZTpiZTJjNWY4YjAwNWQ0NmJkODJkZGIwNDI3YjJkYWIzM18zLTAtMS0xLTQwNzE3_ccffb4f0-4596-48ae-8886-82a29223492d">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Title of each class</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Trading Symbol(s)</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6Y2NiNTk1YmExNzE1NDQ4OTkyZGMzMWE4ZGY4NTE0MzcvdGFibGVyYW5nZTpjY2I1OTViYTE3MTU0NDg5OTJkYzMxYThkZjg1MTQzN18xLTAtMS0xLTQwNzE3_5a559b68-a6d6-474d-bf82-02d8ee81bbcc">Common Stock, par value $0.0001</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6Y2NiNTk1YmExNzE1NDQ4OTkyZGMzMWE4ZGY4NTE0MzcvdGFibGVyYW5nZTpjY2I1OTViYTE3MTU0NDg5OTJkYzMxYThkZjg1MTQzN18xLTItMS0xLTQwNzE3_e20f14c5-dcbe-4ffe-b09c-68c86e00a91e">SLRX</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Nasdaq Capital Market</span></div></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE1_c7116cb5-23fd-4a04-9b5d-ecb77285e1e3">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9744;</span></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described under Item 5.07, on June 14, 2023, the stockholders of Salarius Pharmaceuticals, Inc. (the &#8220;Company&#8221;) voted at the Company&#8217;s 2023 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) to approve the Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan (the &#8220;A&amp;R ESPP&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s Board of Directors previously approved the A&amp;R ESPP, subject to stockholder approval at the Annual Meeting.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The A&amp;R ESPP, among other things, (i) reserves an additional 125,000 shares of common stock of the Company for issuance thereunder, (ii) extends the term of the feature that automatically increases the share reserve annually until January 1, 2028, and (iii) increases the size of the automatic annual increase to an amount equal to the lesser of (a) 2% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of the preceding calendar year and (b) 75,000 shares of common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A copy of the A&amp;R ESPP is filed as Exhibit 10.1 to this report and is incorporated by reference in this Item 5.02. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The material terms of the A&amp;R ESPP as so amended and restated are described in the Company&#8217;s definitive proxy statement on Schedule 14A for the Annual Meeting filed with the Securities and Exchange Commission on May 1, 2023 (the &#8220;Proxy Statement&#8221;).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.277%"><tr><td style="width:1.0%"></td><td style="width:16.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.024%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.07.</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Submission of Matters to a Vote of Security Holders</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 14, 2023, Company held its Annual Meeting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Four proposals were submitted to stockholders at the Annual Meeting as described in the Proxy Statement for the Annual Meeting and voted on at the Annual Meeting. At the Annual Meeting, the stockholders voted and: (1) elected each of the Company&#8217;s three nominees for Class II director; (2) approved the A&amp;R ESPP; (3) approved, by non-binding advisory vote, the compensation of the Company&#8217;s named executive officers as disclosed in the Proxy Statement; and (4) ratified the appointment of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposals and the results of the stockholder votes are as follows:</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1. Proposal to elect three Class II directors to serve until the 2026 annual meeting or until their successors are duly elected and qualified:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.611%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nominees</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Votes For</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Votes Against</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Abstentions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Broker Non-Votes</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">David J. Arthur</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">270,248</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">632</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43,593</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">727,170</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bruce J. McCreedy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">267,578</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">641</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,254</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">727,170</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jonathan Lieber</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">269,684</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">547</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">44,242</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">727,170</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2. Proposal to approve the Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.066%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Votes For</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Votes Against</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Abstentions</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Broker Non-Votes</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">224,289</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">74,630</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15,554</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">727,170</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3. Proposal to provide a non-binding advisory vote on the compensation of the Company&#8217;s named executive officers as disclosed in the Proxy Statement:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.035%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.035%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.035%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.052%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Votes For</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Votes Against</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Abstentions</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Broker Non-Votes</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">216,044</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">85,774</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12,655</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">727,170</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4. Proposal to ratify the appointment of Ernst &amp; Young LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.603%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Votes For</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Votes Against</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Abstentions</span></div></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">913,353</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">103,072</span></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">25,218</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are herewith filed as exhibits to this report: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit Description</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:none" href="salariusespp-4129x2112x032.htm">Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan.</a></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">104</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</span></div></td></tr></table></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.555%"><tr><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.169%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SALARIUS PHARMACEUTICALS, INC.</span></div></td></tr><tr style="height:10pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="18" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date: June 14, 2023</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By:</span></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Mark J. Rosenblum</span></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mark J. Rosenblum</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Financial Officer</span></div></td></tr></table></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>salariusespp-4129x2112x032.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i83d3f01a825244d9a73823a1ea46b3e5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SALARIUS PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2015 EMPLOYEE STOCK PURCHASE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">As Amended and Restated effective as of June 14, 2023</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">GENERAL&#59; PURPOSE.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">ADMINISTRATION.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">To designate from time to time which Related Corporations of the Company will be eligible to participate in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To settle all controversies regarding the Plan and Purchase Rights granted under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To suspend or terminate the Plan at any time as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To amend the Plan at any time as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated to a Committee, the Committee will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">SHARES OF COMMON STOCK SUBJECT TO THE PLAN.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 125,000  shares of Common Stock, plus the number of shares of Common Stock remining available for issuance under the Plan immediately prior to the approval by the Company&#8217;s stockholders of the most recent amendment and restatement of the Plan on the Effective Date, plus the number of shares of Common Stock that are automatically added on January 1st of each year, commencing on January 1, 2024 and ending on (and including) January 1, 2028, in an amount equal to the lesser of (i) 2% of the total number of shares of Capital Stock outstanding on December 31st of the preceding calendar year, and (ii) 75,000 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">GRANT OF PURCHASE RIGHTS&#59; OFFERING.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate, and will comply with the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, inclusive.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered to the Company&#58; (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i) that Offering will terminate immediately as of that first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">ELIGIBILITY.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to Employees of a Related Corporation. Except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee&#8217;s customary employment with the Company or a Related Corporation is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the date on which such Purchase Right is granted will be the &#8220;Offering Date&#8221; of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering, he or she will not receive any Purchase Right under that Offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">No Employee will be eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">As specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#8217;s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Officers of the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">PURCHASE RIGHTS&#59; PURCHASE PRICE.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 15% of such Employee&#8217;s earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In connection with each Offering made under the Plan, the Board may specify (i) a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering and&#47;or (iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#8217;s accumulated Contributions) allocation of the shares of Common Stock available will be made in as nearly a uniform manner as will be practicable and equitable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">PARTICIPATION&#59; WITHDRAWAL&#59; TERMINATION.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by completing and delivering to the Company, within the time specified in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each Participant&#8217;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions. If specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to a Purchase Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#8217;s Purchase Right in that Offering will immediately terminate and the Company will distribute to such Participant all of his or her accumulated but unused Contributions and such Participant&#8217;s Purchase Right in that Offering shall thereupon terminate. A Participant&#8217;s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or (ii) is otherwise no longer eligible to participate. The Company will distribute to such individual all of his or her accumulated but unused Contributions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">During a Participant&#8217;s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Unless otherwise specified in the Offering, the Company will have no obligation to pay interest on Contributions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">EXERCISE OF PURCHASE RIGHTS.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">On each Purchase Date, each Participant&#8217;s accumulated Contributions will be applied to the purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If any amount of accumulated Contributions remains in a Participant&#8217;s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant&#8217;s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such Offering, in which case such amount will be distributed to such Participant after the final Purchase Date, without interest. If the amount of Contributions remaining in a Participant&#8217;s account after the purchase of shares of Common Stock is at least equal to the amount required to purchase one whole share of Common Stock on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such Offering without interest.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 6 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">COVENANTS OF THE COMPANY.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and&#47;or to issue and sell Common Stock upon exercise of such Purchase Rights.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">DESIGNATION OF BENEFICIARY.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares of Common Stock and&#47;or Contributions from the Participant&#8217;s account under the Plan if the Participant dies before such shares and&#47;or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the Participant to change such designation of beneficiary. Any such designation and&#47;or change must be on a form approved by the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and&#47;or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and&#47;or Contributions to the Participant&#8217;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">ADJUSTMENTS UPON CHANGES IN COMMON STOCK&#59; CORPORATE TRANSACTIONS.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust&#58; (i) the class(es) and maximum number of securities subject to the Plan pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (ii) the class(es) and maximum number of securities by which the share reserve is to increase automatically each year pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv) the class(es) and number of securities that are the subject of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">In the event of a Corporate Transaction, then&#58; (i) any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the Participants&#8217; accumulated Contributions will be used to purchase shares of Common Stock within ten business days prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">AMENDMENT, TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing requirements, including any amendment that either (i) materially increases the number of shares of Common Stock available for issuance under the Plan, (ii) materially expands the class of individuals eligible to become Participants and receive Purchase Rights, (iii) materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be purchased under the Plan, (iv) materially extends the term of the Plan, or (v) expands the types of awards available for issuance under the Plan, but in each of (i) through (v) above only to the extent stockholder approval is required by applicable law or listing requirements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted, (ii) as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#8217;s consent if such amendment is necessary to ensure that the Purchase Right and&#47;or the Plan complies with the requirements of Section 423 of the Code.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">EFFECTIVE DATE OF PLAN.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan originally became effective immediately prior to and contingent upon the IPO Date. The Plan as most recently amended and restated is effective as of the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">MISCELLANEOUS PROVISIONS.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant&#8217;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant&#8217;s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a Participant.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&#8217;s conflicts of laws rules.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">DEFINITIONS.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in the Plan, the following definitions will apply to the capitalized terms indicated below&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each and every class of common stock of the Company, regardless of the number of votes per share.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Capitalization Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the common stock of the Company, having 1 vote per share.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Salarius Pharmaceuticals, Inc., a Delaware corporation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Corporate Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">a sale or other disposition of at least 90% of the outstanding securities of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">a merger, consolidation or similar transaction following which the Company is not the surviving corporation&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a member of the Board.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means June 14, 2023, the date the amendment and restatement of the Plan was approved by the stockholders of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Employee who meets the requirements set forth in the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person, including an Officer or Director, who is &#8220;employed&#8221; for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employee Stock Purchase Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a plan that grants Purchase Rights intended to be options issued under an &#8220;employee stock purchase plan,&#8221; as that term is defined in Section 423(b) of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as of any date, the value of the Common Stock determined as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Sections 409A of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">IPO Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date of the underwriting agreement between the Company&#8217;s predecessor, Flex Pharma, Inc., and the underwriter(s) managing the initial public </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">offering of Flex Pharma, Inc.&#8217;s common stock, pursuant to which the common stock was priced for the initial public offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#8220;Offering Document&#8221; approved by the Board for that Offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Offering Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a date selected by the Board for an Offering to commence.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a person who is an officer of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Employee who holds an outstanding Purchase Right.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means this Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Purchase Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means one or more dates during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Purchase Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a period of time specified within an Offering, generally beginning on the Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Purchase Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Related Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ab)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>flks-20230614.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e6b66bbe-b480-4cda-9fdf-3b125d93c7f5,g:fb5a7ef5-6d67-46bd-a018-440b61aed82e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:flks="http://www.flex-pharma.com/20230614" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.flex-pharma.com/20230614">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20230614_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20230614_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.flex-pharma.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>flks-20230614_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e6b66bbe-b480-4cda-9fdf-3b125d93c7f5,g:fb5a7ef5-6d67-46bd-a018-440b61aed82e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_6bb77684-fda2-4740-b6e9-729cfebd6977_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a1eab361-a84d-4cf1-b9f2-217b2b43f092_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_aa4185fc-9ac1-4a77-9290-01f9206d9fd8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c89bce20-1210-4b1b-930f-d5b4946c9893_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0893a564-f5e6-4552-b2fe-d0772faee671_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8684b2b2-9881-446f-ac62-36eaa85f8221_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_5adaba13-19fe-4b6d-9ac9-73d9f170484f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_24efeed2-5e18-4237-8ff4-0352398b0651_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7b2bd747-c85b-46fc-a44a-5e2c6c881ebd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_db016251-ef65-40e2-84b7-9351c17c3fb4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_04417f80-be2c-46b5-8209-4333f0cc2d6a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_daa8e18d-15b6-422a-a76f-4116410787d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_57902f6c-953c-42dd-b70d-b56fbac56175_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5e15ff53-dac9-46e5-afbf-0913ee6b0f40_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1a31e817-19e5-48ef-8dd2-de9024d8c16d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b737ef4f-3b18-4b01-9fe0-66e837e5202f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_71ab3794-f64f-4e7f-8b96-0963b3c3b31e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_463191a6-1a94-4e25-a4e6-1adfacd36ec4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_efb865fe-f706-4ae4-901d-537b2bd3fc55_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f262c687-14b2-4b07-8c57-2d6f3556acbf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_56a1fa49-5cff-4b15-bac9-2e6512c4b66b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_64b7c5ab-e86c-45f5-b1da-03ad0f84283e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>flks-20230614_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:e6b66bbe-b480-4cda-9fdf-3b125d93c7f5,g:fb5a7ef5-6d67-46bd-a018-440b61aed82e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CoverPage" xlink:type="simple" xlink:href="flks-20230614.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e2408bbd-246f-4048-b87a-5977452d600c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_DocumentType_e2408bbd-246f-4048-b87a-5977452d600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a984aa41-ce27-479f-a994-9816afa0c6cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_DocumentPeriodEndDate_a984aa41-ce27-479f-a994-9816afa0c6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0851d683-d2e8-4ffd-9319-5e8940eea370" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityRegistrantName_0851d683-d2e8-4ffd-9319-5e8940eea370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f159b43d-78e7-48f1-b6ca-8a77186ba147" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f159b43d-78e7-48f1-b6ca-8a77186ba147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_73f38aa9-9bd9-4d19-922f-5944e28de33b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityFileNumber_73f38aa9-9bd9-4d19-922f-5944e28de33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b22598de-2fe5-4d3a-878c-82ce6a7db695" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityTaxIdentificationNumber_b22598de-2fe5-4d3a-878c-82ce6a7db695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1026fff1-9791-4664-97af-a145874b1b69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityAddressAddressLine2_1026fff1-9791-4664-97af-a145874b1b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_58c75c77-7a0f-463d-bcb4-e8ffb284f8ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityAddressAddressLine1_58c75c77-7a0f-463d-bcb4-e8ffb284f8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2570c7a1-bcc6-445d-8db6-2d993b74c605" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityAddressCityOrTown_2570c7a1-bcc6-445d-8db6-2d993b74c605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6f4d83cf-abdd-4df2-927e-b7a7a3fe7156" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityAddressStateOrProvince_6f4d83cf-abdd-4df2-927e-b7a7a3fe7156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_33108035-19e9-4331-b5c4-8868d61e7c2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityAddressPostalZipCode_33108035-19e9-4331-b5c4-8868d61e7c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e38b689b-f8d0-49e4-ae32-2031a6901000" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_CityAreaCode_e38b689b-f8d0-49e4-ae32-2031a6901000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7aa54f88-ceb2-47fc-acf2-2d5da82220ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_LocalPhoneNumber_7aa54f88-ceb2-47fc-acf2-2d5da82220ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_522644e0-7dbb-4558-a2b1-fa0e66f4b590" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_WrittenCommunications_522644e0-7dbb-4558-a2b1-fa0e66f4b590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_afd450da-f878-4c96-9a78-7d01f04a6d02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_SolicitingMaterial_afd450da-f878-4c96-9a78-7d01f04a6d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f3f531bd-3cbd-4fc4-b2a1-b2c342d4ae03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_PreCommencementTenderOffer_f3f531bd-3cbd-4fc4-b2a1-b2c342d4ae03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d8b5005c-04c4-40bf-ab4a-45b9b1b30e1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d8b5005c-04c4-40bf-ab4a-45b9b1b30e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4dc76d40-0100-4eb5-928c-04f5e53f4c31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_Security12bTitle_4dc76d40-0100-4eb5-928c-04f5e53f4c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_68ce771d-8a36-405d-8474-2bc78ff9fd77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_TradingSymbol_68ce771d-8a36-405d-8474-2bc78ff9fd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4e51f957-4c6b-4c5d-8eee-e3d15301f844" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityEmergingGrowthCompany_4e51f957-4c6b-4c5d-8eee-e3d15301f844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ac03098c-018d-4dc9-832d-768527f8b006" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_EntityCentralIndexKey_ac03098c-018d-4dc9-832d-768527f8b006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d9ea4f95-c053-49a6-bb44-651c5ba570aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cd4f28b4-57f5-4f7d-94f8-8afea858b09e" xlink:to="loc_dei_AmendmentFlag_d9ea4f95-c053-49a6-bb44-651c5ba570aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140343579177248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 16, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 14,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SALARIUS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5087339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite X<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2450 Holcombe Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">834-9144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001615219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>flks-20230614_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="flks-20230614.xsd" xlink:type="simple"/>
    <context id="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M180L2ZyYWc6OWJmMTk2ZTAwMzkyNDFiNzkwODFhODM0ZGIxOTU3MGIvdGFibGU6N2I5ZDg1YjFiYzY2NDFmMmE1ZGI5OWEwZWFiNjRkMDcvdGFibGVyYW5nZTo3YjlkODViMWJjNjY0MWYyYTVkYjk5YTBlYWI2NGQwN18xLTEtMS0xLTQwNzE3_a49d8f98-0ded-4b41-a67a-87cd25129be8">0001615219</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M180L2ZyYWc6OWJmMTk2ZTAwMzkyNDFiNzkwODFhODM0ZGIxOTU3MGIvdGFibGU6N2I5ZDg1YjFiYzY2NDFmMmE1ZGI5OWEwZWFiNjRkMDcvdGFibGVyYW5nZTo3YjlkODViMWJjNjY0MWYyYTVkYjk5YTBlYWI2NGQwN18yLTEtMS0xLTQwNzE3_333b8a7c-f1d6-48c2-9760-5965a15453fe">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE2_e36fc5b0-a971-4347-8255-36e13a591f0b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N18yMjM_a7615e28-8339-462a-b722-d9bd8450dc92">2023-06-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE3_5231f271-1b89-4114-9d21-9e82ec1839ed">SALARIUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8wLTAtMS0xLTQwNzE3_9598cced-1830-43ed-aa07-d10c3de9dc81">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8wLTItMS0xLTQwNzE3_70b093df-788f-49a9-931f-df41d17edd33">001-36812</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8wLTYtMS0xLTQwNzE3_0e58ea57-97e9-49a5-82ae-9951a196453b">46-5087339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTAtMS0xLTQwNzE3L3RleHRyZWdpb246MjZhOGVjMWVlZTExNDg3NThkNzRiZDgxMGM5ZDEyMWRfNQ_657e2a29-2500-431b-ad0c-5ea113235e99">2450 Holcombe Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTAtMS0xLTQwNzE3L3RleHRyZWdpb246MjZhOGVjMWVlZTExNDg3NThkNzRiZDgxMGM5ZDEyMWRfOA_7f3b07b5-aa32-4fda-91d0-d12acee01cc8">Suite X</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTAtMS0xLTQwNzE3L3RleHRyZWdpb246MjZhOGVjMWVlZTExNDg3NThkNzRiZDgxMGM5ZDEyMWRfMTE_0ffd9cc1-7208-4acb-9be0-763d0f2593a8">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTAtMS0xLTQwNzE3L3RleHRyZWdpb246MjZhOGVjMWVlZTExNDg3NThkNzRiZDgxMGM5ZDEyMWRfMTU_622cf71b-e3b7-430a-ba60-d8feb81abc3a">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6ZGQ1MjJhNzJhNjI2NGVlYjhhNzUzY2NlZmVhNDNhMmEvdGFibGVyYW5nZTpkZDUyMmE3MmE2MjY0ZWViOGE3NTNjY2VmZWE0M2EyYV8zLTQtMS0xLTQwNzE3_95310ab2-b16a-4a5e-9bdb-1f886f02e1aa">77021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE4_1f791fda-b0ef-4e42-9499-319a93d2b251">832</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE5_f21b001c-7a6c-443b-ba96-26019f9b6411">834-9144</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6YmUyYzVmOGIwMDVkNDZiZDgyZGRiMDQyN2IyZGFiMzMvdGFibGVyYW5nZTpiZTJjNWY4YjAwNWQ0NmJkODJkZGIwNDI3YjJkYWIzM18wLTAtMS0xLTQwNzE3_2f967157-e4bc-4d9f-9566-973a1ae271d0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6YmUyYzVmOGIwMDVkNDZiZDgyZGRiMDQyN2IyZGFiMzMvdGFibGVyYW5nZTpiZTJjNWY4YjAwNWQ0NmJkODJkZGIwNDI3YjJkYWIzM18xLTAtMS0xLTQwNzE3_7c78a720-422b-4943-83ea-cbad5fc9b831">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6YmUyYzVmOGIwMDVkNDZiZDgyZGRiMDQyN2IyZGFiMzMvdGFibGVyYW5nZTpiZTJjNWY4YjAwNWQ0NmJkODJkZGIwNDI3YjJkYWIzM18yLTAtMS0xLTQwNzE3_5776e6a5-3ca2-4278-98b9-87b06bb22fa6">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6YmUyYzVmOGIwMDVkNDZiZDgyZGRiMDQyN2IyZGFiMzMvdGFibGVyYW5nZTpiZTJjNWY4YjAwNWQ0NmJkODJkZGIwNDI3YjJkYWIzM18zLTAtMS0xLTQwNzE3_ccffb4f0-4596-48ae-8886-82a29223492d">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6Y2NiNTk1YmExNzE1NDQ4OTkyZGMzMWE4ZGY4NTE0MzcvdGFibGVyYW5nZTpjY2I1OTViYTE3MTU0NDg5OTJkYzMxYThkZjg1MTQzN18xLTAtMS0xLTQwNzE3_5a559b68-a6d6-474d-bf82-02d8ee81bbcc">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGFibGU6Y2NiNTk1YmExNzE1NDQ4OTkyZGMzMWE4ZGY4NTE0MzcvdGFibGVyYW5nZTpjY2I1OTViYTE3MTU0NDg5OTJkYzMxYThkZjg1MTQzN18xLTItMS0xLTQwNzE3_e20f14c5-dcbe-4ffe-b09c-68c86e00a91e">SLRX</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwYzE2MjIxZmMzZjQ2YzQ4MjRmNWJiMTc5YmQxODczL3NlYzo5MGMxNjIyMWZjM2Y0NmM0ODI0ZjViYjE3OWJkMTg3M18xL2ZyYWc6Y2I1Mzk4YWZhNDBkNDM4Yjk3MmRjMmM3MmE4ZjU0ODcvdGV4dHJlZ2lvbjpjYjUzOThhZmE0MGQ0MzhiOTcyZGMyYzcyYThmNTQ4N185NDE1_c7116cb5-23fd-4a04-9b5d-ecb77285e1e3">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<09STGX [Q=*F8^&/<"6_W\8_ U02P,$%     @ YI7.5I^@&_"Q @  X@P
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( .:5SE8'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ YI7.5C3/
M[LOO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ YI7.5IE<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #FE<Y6:@VZS$L$  "+
M$   &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ YI7.5I^@&_"Q @  X@P   T              ( !CPP
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #FE<Y6EXJ[',     3 @  "P
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52P4&      D "0 ^ @  YQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="flks-20230614.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="flks-20230614.htm">flks-20230614.htm</File>
    <File>flks-20230614.xsd</File>
    <File>flks-20230614_lab.xml</File>
    <File>flks-20230614_pre.xml</File>
    <File>salariusespp-4129x2112x032.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "flks-20230614.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "flks-20230614.htm"
     ]
    },
    "labelLink": {
     "local": [
      "flks-20230614_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "flks-20230614_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "flks-20230614.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "flks",
   "nsuri": "http://www.flex-pharma.com/20230614",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230614.htm",
      "contextRef": "iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.flex-pharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230614.htm",
      "contextRef": "iabd4a969a6ff4aeda6e554f2faef407f_D20230516-20230516",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001615219-23-000055-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001615219-23-000055-xbrl.zip
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MYX-1#VYFI*STD!6V74B;,V2@W9 +P\B_A2$"IW[R/X/=!:^X9L+%Y3$+KO^
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M)41O3:&D[WJS_XSZ(=SJ%:4AK(*\FFI>SY?B%$B@3:C%*3#Y-JGM.TGF'%<
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MVC3P>)DY#DB4A1\U2,O$0Q\!C@Z2=AC!X-PU%?*UY(*6;LB^PL7"^NM<K*?
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MD^6! \(!!W>#PJ$3CI<1P!D/(\8E<O6*!+H ,\A Y+D*")_A"!,>A9'7-R.
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M',4. /F*Z4%PJ*G#,5;3B8)!"J&]$EXII"S.VRF9ET+GLTJ@8W149X5B_$?
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MQ-]Y, R4"7<M=RKQ2R\HX"_SHGA#J+LHVPH*'KR2@6/4U<"(@Q-YIZR[4*(
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MSK+^:O%$O+-\X&CO[H?NI?N__-'>_P!02P,$%     @ YI7.5L8CA01R+
MXD@! !X   !S86QA<FEU<V5S<' M-#$R.7@R,3$R># S,BYH=&WM?>ESVTB6
MY_?]*[#5VSU2!*S1Y;NF(M@R[6*-+3DDN6K[TT822(IH@P"-0S+KKY]WY F
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M&'YH!L, J,N+IP;#9= A=LT5'E*0V6XLJX=RA@$=HDXP^"&'B/$AQ4T]4?A
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M+FAT;5!+ 0(4 Q0    ( .:5SE8F9MH*<P(  (8'   1              "
M <@;  !F;&MS+3(P,C,P-C$T+GAS9%!+ 0(4 Q0    ( .:5SE9W$HE/0 H
M %9=   5              "  6H>  !F;&MS+3(P,C,P-C$T7VQA8BYX;6Q0
M2P$"% ,4    " #FE<Y6I3WS[ZH&  #_,   %0              @ '=*
M9FQK<RTR,#(S,#8Q-%]P<F4N>&UL4$L! A0#%     @ YI7.5L8CA01R+
MXD@! !X              ( !NB\  '-A;&%R:75S97-P<"TT,3(Y>#(Q,3)X
=,#,R+FAT;5!+!08     !0 % % !  !H7      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
